| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | Q16CT95N25 |
Pharmacology
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | 3 | D002289 | ClinicalTrials |
| Pancreatic Neoplasms | 2 | D010190 | ClinicalTrials |
| Carcinoma, Hepatocellular | 2 | D006528 | ClinicalTrials |
| Carcinoma | 2 | D002277 | ClinicalTrials |
| Glioblastoma | 2 | D005909 | ClinicalTrials |
| Triple Negative Breast Neoplasms | 2 | D064726 | ClinicalTrials |
| Carcinoma, Squamous Cell | 2 | D002294 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Hepatitis C | 1 | D006526 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Melanoma | 1 | D008545 | ClinicalTrials |
| Breast Neoplasms, Male | 1 | D018567 | ClinicalTrials |
| Rectal Neoplasms | 1 | D012004 | ClinicalTrials |
| Prostatic Neoplasms | 1 | D011471 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 648904-28-3 |
| ChEMBL | CHEMBL1742989 |
| FDA SRS | Q16CT95N25 |
| Guide to Pharmacology | 8002 |
CONTENTS